Market Place
Sourcing Support
Kite Presents Yescarta Data For Earlier Treatment Lines
14 Jun 2024 //
BUSINESSWIRE
Poseida examines CAR-T conditioning to crack into solid tumors
10 Apr 2024 //
FIERCE BIOTECH
Kite Gilead’s Kite shortens Yescarta manufacturing time with FDA nod
31 Jan 2024 //
FIERCE PHARMA
U.S. FDA Approves Label Update for Kite’s Yescarta® CAR T-Cell Therapy
21 Dec 2023 //
BUSINESSWIRE
Long-Term Data for Kite’s Yescarta® CAR T-Cell Therapy Presented at ASH 2023
11 Dec 2023 //
BUSINESSWIRE
Analyses of Kite’s Yescarta®CAR T-Cell Therapy Support Curative Potential in Patients With Non-Hodgkin Lymphomas
11 Dec 2023 //
BUSINESSWIRE
Kite’s Car T-cell Therapy Yescarta Showes Durable Remission in ALYCANTE Study
18 Sep 2023 //
PRESS RELEASE
Kite Announces Completion of Marketing Authorization Transfer for Yescarta®
22 Jun 2023 //
BUSINESSWIRE
Kite’s Yescarta and Tecartus therapies show promise
12 Jun 2023 //
PHARMATIMES
Gilead`s Yescarta cuts risk of death by 27.4% in lymphoma study
06 Jun 2023 //
BUSINESSWIRE
Gilead posts big gains for cell therapies and Trodelvy
28 Apr 2023 //
FIERCE PHARMA
Kite`S Yescarta First Car T-Cell Therapy To Receive Health Canada Authorization
24 Mar 2023 //
NEWSWIRE
Gilead`s Yescarta scoops up overall survival win
22 Mar 2023 //
FIERCE PHARMA
BMS, Pfizer turned away from SCOTUS in high-profile cases
09 Jan 2023 //
FIERCE PHARMA
Yescarta Approved in Japan for Treatment of Refractory Large B-Cell Lymphoma
22 Dec 2022 //
PRESS RELEASE
Yescarta® Now Approved in Japan for Relapsed/Refractory Large B-Cell Lymphoma
22 Dec 2022 //
BUSINESSWIRE
Analyses of Tecartus CAR T-Cell Therapy Provide Evidence Supporting Survival
12 Dec 2022 //
BUSINESSWIRE
Three-Year Follow-Up Analysis of Kite’s Yescarta® CAR T-cell Therapy
12 Dec 2022 //
BUSINESSWIRE
Time to CAR T-cell Therapy May Impact Outcomes for Patients
11 Dec 2022 //
BUSINESSWIRE
Body of Evidence Grows From ZUMA-7 Supporting Treatment With Yescarta Therapy
11 Dec 2022 //
BUSINESSWIRE
Daiichi is handing back Yescarta rights to Gilead and Kite
09 Dec 2022 //
FIERCEPHARMA
Gilead, fueled by latest approval, sees CAR-T sales take off
29 Oct 2022 //
BIOPHARMADIVE
NDA for Indication of CAR T-Cell Therapy Product YIKAIDA Approved for CDE Review
27 Oct 2022 //
PRNEWSWIRE
Kite’s Yescarta First CAR T-cell Therapy to Receive EMA for B-cell Lymphoma
18 Oct 2022 //
BUSINESSWIRE
Atara on verge of landmark approval for first allogeneic T-cell therapy
15 Oct 2022 //
FIERCEPHARMA
Gilead Sciences’ push into oncology is paying off, as Veklury falters
03 Aug 2022 //
PHARMAPHORUM
Kite’s CAR T-cell Therapy Yescarta Granted MAA for r/r Follicular Lymphoma
28 Jun 2022 //
BUSINESSWIRE
BMS` CAR-T pressures Gilead in 2L lymphoma with broader nod
25 Jun 2022 //
FIERCEPHARMA
Landmark ZUMA-7 Trial Reinforce Yescarta CAR T-cell Superiority Over SOC
04 Jun 2022 //
BUSINESSWIRE
Yescarta CAR T-cell Therapy Demonstrates Consistent Survival Outcomes
03 Jun 2022 //
BUSINESSWIRE
Gilead assembles CAR-T manufacturing troika with new FDA nod
20 Apr 2022 //
FIERCEPHARMA
Gilead`s Kite leads CAR-T class to 2L lymphoma
02 Apr 2022 //
FIERCEPHARMA
FDA Approves New Label Update for CAR T-Cell Therapy Yescarta
31 Jan 2022 //
BUSINESSWIRE
Intellia bags option on Kyverna’s autoimmune CAR-T prospect
06 Jan 2022 //
BIOSPACE
Gilead`s Yescarta could get $1.5B sales in 2L lymphoma: analyst
17 Dec 2021 //
FIERCEPHARMA
Yescarta CAR T-Cell Therapy Quadruples Median Event-Free Survival Duration Over
11 Dec 2021 //
BUSINESSWIRE
Yescarta Demonstrates Durable 2-Year Clinical Benefit in NHL
11 Dec 2021 //
BUSINESSWIRE
Intima snags Gilead`s former Yescarta leader for cell Tx chops
11 Nov 2021 //
FIERCEBIOTECH
Blackstone bets on Autolus` CD19 CAR-T in $250M deal
09 Nov 2021 //
WALLSTREETJOURNAL
CRISPR Therapeutics` CAR-T Cancer Therapy Shows Early Promise
13 Oct 2021 //
BIOSPACE
Kite Submits Suppl. BLA to USFDA for Earlier Use of Yescarta in Large BCL
30 Sep 2021 //
PRESS RELEASE
Gilead`s Kite earns second-line win for CAR-T Yescarta
29 Jun 2021 //
ENDPTS
Fosun Kite gains first CAR T-cell therapy approval in China
23 Jun 2021 //
BIOSPECTRUMASIA
CAR T-Cell Therapy Bests Currently Available Therapies: Presented at EHA
18 Jun 2021 //
FIRSTWORDPHARMA
Yescarta provides sustained survival benefit vs current therapies in FL
14 Jun 2021 //
PHARMALETTER
Positive Data for Yescarta in Relapsed or Refractory Follicular Lymphoma
14 Jun 2021 //
BUSINESSWIRE
Kite`s YESCARTA® (Axicabtagene Ciloleucel) Reimbursed in Alberta
23 Apr 2021 //
NEWSWIRE
Gilead`s Yescarta scored the industry`s first CAR-T nod in follicular lymphoma
10 Mar 2021 //
FIERCE PHARMA
Kite`s YESCARTA (Axicabtagene Ciloleucel) Reimbursed in Ontario
10 Dec 2020 //
BIOSPACE
ASH: Gilead`s CAR-T med Yescarta shows promise earlier in lymphoma therapy
08 Dec 2020 //
FIERCE PHARMA
Gilead`s Yescarta shows promise earlier in lymphoma therapy
07 Dec 2020 //
FIERCE PHARMA
Yescarta® Is First CAR T-cell Therapy to Demonstrate High Response Rates
05 Dec 2020 //
BUSINESSWIRE
From natural killer cells to off-the-shelf CAR-Ts, biopharma targets cancer
15 Sep 2020 //
FIERCEBIOTECH
CIBMTR Completes Enrollment in Yescarta® Long-Term Post-Marketing Safety Study
08 Sep 2020 //
BUSINESSWIRE
Kite looks to expand Yescarta franchise with new indications; Tiny Lixte looks
04 Sep 2020 //
ENDPTS
Novartis eyes 3rd Kymriah indication in follicular lymphoma
05 Aug 2020 //
FIERCE PHARMA
FDA hands MorphoSys and Incyte a quick OK on their potential blockbuster CAR-T
04 Aug 2020 //
ENDPTS
FDA Approvals Roundup: Tecartus, Breztri Aerosphere, Wynzora
30 Jul 2020 //
RAPS
Navigating Complexity in Oncology Cell and Gene Therapy Clinical Trials
24 Jul 2020 //
CLINICALTRIALSARENA
